human growth hormone is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-15. Numbers and descriptions here follow the published literature rather than marketing material.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
On 7 December 2024, Syrian rebels announced that they had started surrounding Damascus after capturing nearby towns, with rebel commander Hassan Abdul Ghani stating: "Our forces have begun implementing the final phase of encircling the capital Damascus." The rebels started encircling the capital after capturing Al-Sanamayn, a town 20 kilometres (12 mi) from the southern entrance of Damascus. In the Rif Dimashq region, pro-government forces withdrew from the towns of Assal al-Ward, Yabroud, Flitah, Al-Naseriyah and Artouz, while rebels came within 10 kilometres (6.2 mi) of Damascus. The Syrian government denied claims that its army had withdrawn from positions near the city. By the evening, pro-government forces had left the towns on the outskirts of Damascus, including Jaramana, Qatana, Muadamiyat al-Sham, Darayya, Al-Kiswah, Al-Dumayr, Daraa and sites near the Mezzeh Air Base. Maher al-Assad and his 4th Division were reportedly among the few loyalists who still tried to defend the city; his second-in-command was later found dead in his office, possibly indicating violent disputes over the orders and escapes of many military officers. According to the Syrian Observatory for Human Rights, Syrian rebels were active in the Damascus suburbs of Jaramana, Muadamiyah, and Darayya, and were marching from the east toward Harasta. In the main square of Jaramana, protestors took down a statue of Hafez al-Assad. In the evening, pro-government forces reportedly withdrew from several suburbs where large-scale protests broke out.
Necrophages can be classified according to their nutritional reliance on carrion and also their level of adaptation to carrion feeding. Animals are described as 'obligate necrophages' if they use carrion as their sole or main food source and depend on carrion for survival or reproduction. The term 'specialists' is also sometimes used in recognition that these animals have traits favoring necrophagy and making other feeding behaviors difficult. For example, large wingspans facilitate the energy-efficient gliding vultures need to cover long distances in search of carrion, but reduce the agility needed to kill prey. Animals that eat carrion opportunistically and retain the traits needed to find and consume other food sources are described as 'facultative necrophages' and 'generalists'. Both obligate and facultative necrophages are sometimes sub-classified as 'wet' and 'dry' feeders. These terms differentiate animals feeding on moist, putrefying tissue from animals feeding on desiccated and keratinized tissues.
Peterson JA, Kusunose M, Kusunose E, Coon MJ (1967). "Enzymatic omega-oxidation. II. Function of rubredoxin as the electron carrier in omega-hydroxylation". J. Biol. Chem. 242 (19): 4334–40. doi:10.1016/S0021-9258(18)99543-8. PMID 4294330. "Enzymatic -oxidation. VI. Isolation of homogeneous reduced diphosphopyridine nucleotide-rubredoxin reductase". J. Biol. Chem. 247 (7): 2109–16. 1972. PMID 4335861. Ueda T, Coon MJ (1972). "Enzymatic oxidation. VII. Reduced diphosphopyridine nucleotide-rubredoxin reductase: properties and function as an electron carrier in hydroxylation". J. Biol. Chem. 247 (16): 5010–6. doi:10.1016/S0021-9258(19)44932-6. PMID 4403503. Petitdemange H, Marczak R, Blusson H, Gay R (1979). "Isolation and properties of reduced nicotinamide adenine dinucleotiderubredoxin oxidoreductase of Clostridium acetobutylicum". Biochem. Biophys. Res. Commun. 91 (4): 1258–65. Bibcode:1979BBRC...91.1258P. doi:10.1016/0006-291X(79)91202-6. PMID 526302.
== Variant tags == This tag is also known as the C-terminal TAP tag because an N-terminal version is also available. However, the method to be described assumes the use of a C-terminal tag, although the principle behind the method is still the same.
Bivalves and the gastropods in the family Juliidae have very similar shells. There are limpet-like forms in several lines of gastropods: "true" limpets, pulmonate siphonariid limpets and several lineages of pulmonate freshwater limpets. Cephalopod (like in octopuses and squid) and vertebrate eyes are both lens-camera eyes with much overall similarity, yet are very unrelated species. A closer examination reveals some differences including embryonic development, extraocular muscles, number of lens parts, and the lack of a retinal blindspot in the cephalopod eye. Swim bladders: buoyant bladders independently evolved in fishes, the tuberculate pelagic octopus, and siphonophores such as the Portuguese man o' war. Bivalves and brachiopods independently evolved paired hinged shells for protection. However, the anatomy of their soft parts is very dissimilar, which is why molluscs and brachiopods are put into different phyla. Jet propulsion in squids and in scallops: these two groups of mollusks have very different ways of squeezing water through their bodies in order to power rapid movement through a fluid. (Dragonfly larvae in the aquatic stage also use an anal jet to propel them, and jellyfish have used jet propulsion for a very long time.) Sea hares (gastropod molluscs) employ a similar means of jet propulsion, but without the sophisticated neurological machinery of cephalopods they navigate somewhat more clumsily. Tunicates (such as salps), and some jellyfish also employ jet propulsion.
Sources: en.wikipedia.org
=== September === 1 September – John Swinney gives his keynote speech to the SNP Annual Conference, saying that he will put the "people's priorities" at the heard of the Scottish Government, and that he will work to convince voters that Scottish independence is the "route" to delivering a fairer and stronger country. 2 September – The Scottish Government confirms that all young offenders under the age of 18 have been removed from Scotland's young offenders' institutions and transferred to more child-friendly accommodation. 3 September – In a statement to the Scottish Parliament, Finance Secretary Shona Robison outlines £500m of spending cuts. She argues the cuts are needed because of an additional £800m in financial costs brought about by public sector pay deals, austerity from Westminster, inflation, the COVID-19 pandemic and the Russian invasion of Ukraine. BBC News reports that the headquarters of GB Energy, the new government-backed energy company, will be in Aberdeen. Members of the Unison trade union working for councils in Scotland reject an annual pay increase offer worth 3.6%, equivalent to at least £1,292. 4 September – The Scottish Government abandons an unfulfilled commitment to expand free school meals to all primary school pupils. 5 September – Scottish rugby player Scott Hastings confirms his wife, Jenny Hastings, has been reported missing after disappearing at a location used for wild swimming in the Firth of Forth on 3 September.
It is complex, multi-factorial, and likely to be also represented by a series of sub-groups driven by pain varying from peripheral or central nervous system, altered laxity/stiffness of muscles, laxity to injury of tendinous/ligamentous structures to maladaptive body mechanics.
In a separate study of rehabilitative strength training following immobilization, creatine supplementation was associated with increased muscle MRF4 protein expression; however, whether changes in MRF4 directly mediate myonuclear accretion or hypertrophy remains uncertain.
=== Sexual === Isotretinoin is also associated with permanent sexual side effects, namely erectile dysfunction and reduced libido. In October 2017, the UK MHRA issued a Drug Safety Update to physicians in response to reports of these problems. This was in response to an EU review, published in August 2017, which states that a plausible physiological explanation of these side effects "may be a reduction in plasma testosterone". The review also stated that "the product information should be updated to include 'sexual dysfunction including erectile dysfunction and decreased libido' as an undesirable effect with an unknown frequency". There have also been reports of spermatogenesis disorders, such as oligospermia. 27 cases of sexual dysfunction report either negative dechallenge or positive dechallenge.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.